Literature DB >> 23404726

The ocular disease of Aristodemus and Eurytus 480 BC: diagnostic considerations.

Barend F Hogewind, Joannes A F Coebergh, Niels C Gritters-van den Oever, Michiel W P de Wolf, Gerard J van der Wielen.   

Abstract

OBJECTIVE: In the historic description of Herodotus on the battle of Thermopylae at 480 BC two formerly healthy warriors suffer from "ophthalmia". The purpose of this study is to assess the possible aetiologies of this disease.
DESIGN: We studied Herodotus' description in translation and offer a differential diagnosis.
RESULTS: From the text we deduced that the "ophthalmia" was a condition in two physically fit males with a bilateral decreased or distorted vision, lasting longer than an hour, with an acute or subacute onset in Ancient Greece. The condition ultimately went into remission in one of the two patients, whereas the other subject deceased in combat not long after the onset of the disease, still suffering from the disease. The differential diagnosis consists of (1) anticholinergic syndrome secondary to an intoxication with the berries of the plant Atropa belladonna, (2) automutilation and (3) psychogenic loss of visual acuity.
CONCLUSION: It is impossible to assess the ultimate cause of the "opthalmia" after 2500 years, but we suggest the anticholinergic syndrome by intoxication with Atropa belladonna is the most likely.

Entities:  

Mesh:

Year:  2013        PMID: 23404726     DOI: 10.1007/s10792-012-9638-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  2 in total

1.  Acute anticholinergic syndrome from Atropa belladonna mistaken for blueberries.

Authors:  A Mateo Montoya; N Mavrakanas; J S Schutz
Journal:  Eur J Ophthalmol       Date:  2009 Jan-Feb       Impact factor: 2.597

2.  Pattern visual evoked potentials in the assessment of visual acuity in malingering.

Authors:  Fatih C Gundogan; Gungor Sobaci; Atilla Bayer
Journal:  Ophthalmology       Date:  2007-07-05       Impact factor: 12.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.